Clozapine Reduces Recurrent Suicidal and Self-Injurious Behavior in Treatment-Refractory Incarcerated Individuals

J Correct Health Care. 2022 Oct;28(5):329-335. doi: 10.1089/jchc.21.02.0014. Epub 2022 Sep 30.

Abstract

This retrospective review examines clozapine's effects on treatment-refractory incarcerated individuals (N = 23) with recurrent thoughts of self-harm and/or self-injurious behavior. Emergent suicide risk assessments and days on suicide watch were assessed for the 3 months pre- and post-clozapine treatment. Total suicide assessments fell from 73 pre- to 14 post-clozapine, with a median of 2 assessments (interquartile range [IQR]: 1,5) pre-clozapine compared with 0 (IQR: 0,1) post-clozapine (p < 0.0001). Total days on suicide watch decreased from 104 days pre- to 32 post-clozapine, with a median of 3 days (IQR: 0,9) pre-clozapine compared with 0 (IQR: 0,0) post-clozapine (p = 0.0012). Emergency room visits and medical hospitalizations decreased substantially for all months of treatment. Clozapine treatment was associated with marked reductions in self-injurious thoughts and behaviors in high-risk incarcerated individuals.

Keywords: clozapine; prisons; self-injurious behavior; suicide.

MeSH terms

  • Clozapine* / therapeutic use
  • Humans
  • Prisoners*
  • Self-Injurious Behavior* / drug therapy
  • Self-Injurious Behavior* / epidemiology
  • Suicidal Ideation
  • Suicide*

Substances

  • Clozapine